Promedior

After BMS walked away from Promedior, Roche to acquire the fibroid-treatment firm for $1.4B

Roche will provide $390 million in cash upfront and then provide milestone payments to acquire Promedior, which is developing a drug to treat a rare and fatal lung disease.

By Arundhati Parmar

Morning Read: Bristol-Myers Squibb will acquire immunotherapy group Promedior for $1.25B

Bristol-Myers Squibb has paid for the right to acquire US clinical stage immunotherapy group Promedior in a deal valued at up to $1.25 billion, securing access to the firm’s fibrotic disease candidates.

By Nicole Oran